AdvisorShares Psychedelics ETF (PSIL) — ()

Key Metrics

 

News

Groovy: Psychedelics ETF PSIL a Top-5 Active ETF YTD

Published: by:
Sentiment: Positive ()

2025 is drawing to a close, and investors have plenty to look back on. Active ETF performance and proliferation was once again an important theme, and as the category matures, …

Read More
image for news Groovy: Psychedelics ETF PSIL a Top-5 Active ETF YTD
This Psychedelics ETF Has Investors Going Crazy (In a Good Way)

Published: by:
Sentiment: Positive ()

When it comes to curing common ailments, the majority of doctors won't be prescribing things like LSD, mescaline, PCP, or psilocybin (mushrooms) anytime soon. But these are examples of a …

Read More
image for news This Psychedelics ETF Has Investors Going Crazy (In a Good Way)
5 ETFs That Beat the Market in the First Half of 2025

Published: by:
Sentiment: Positive ()

SGDM, SLVP, SHLD, URA and PSIL top the charts in the first half of 2025, defying market turmoil and riding sector-specific surges.

Read More
image for news 5 ETFs That Beat the Market in the First Half of 2025
5 Sector ETFs That Have Outperformed the S&P 500 in Q1

Published: by:
Sentiment: Positive ()

Here are a few ETFs that have outperformed the S&P 500 in the first quarter.

Read More
image for news 5 Sector ETFs That Have Outperformed the S&P 500 in Q1
5 Best-Performing Sector ETFs Halfway Through Q1

Published: by:
Sentiment: Positive ()

At mid-way through the first quarter, Wall Street has been on a bull run, outplaying tariff trade war fears.

Read More
image for news 5 Best-Performing Sector ETFs Halfway Through Q1

About AdvisorShares Psychedelics ETF PSIL

The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and derivatives that have economic characteristics similar to such securities. The fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The fund is non-diversified.